Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Rank in Stocks #21012
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Share Price
$7.12
Last synced: 2023-03-08
Market Cap
$117.03M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade F-star Therapeutics, Inc. (FSTX)

Category

Stock price history for F-star Therapeutics, Inc. (FSTX)
Highest end of day price: $6.19 on 2023-03-01

Lowest end of day price: $7.22 on 2021-05-01
Stock price history of F-star Therapeutics, Inc. from 2021 to 2026
Annual Stock Price Performance
Year Performance
2023 14.14%
2022 6.74%
2021 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH